US authorises increased production of Takeda’s ADHD drug to address shortages
The US Drug Enforcement Administration has increased the production limit for Takeda Pharmaceuticals’ ADHD drug Vyvanse and its generics have increased in price by about 24 per cent to address the ongoing shortage of the drug in the United States.
ENTRADAS POPULARES
Putin may discuss Ukraine peace deal with Trump
noviembre 22, 2024
Spain’s vice-president Ribera blames floods on climate change
noviembre 22, 2024
Storm lashes northwestern US, killing two people
noviembre 22, 2024
Iceland volcano erupts for tenth time in three years
noviembre 22, 2024
TRANSMISIÓN EN VIVO